Showing 1731-1740 of 3239 results for "".
- Sienna Labs Obtains Fifth Patent Relating to Use of Plasmonic Nanoparticles in Treatment of Sebaceous Glands and Hairhttps://practicaldermatology.com/news/sienna-labs-obtains-fifth-patent-relating-to-use-of-plasmonic-nanoparticles-in-treatment-of-sebaceous-glands-and-hair/2459048/Siienna Labs was issued US Patent No. 8,895,071 covering, among other aspects, methods of using the company's plasmonic nanoparticle platform for localizing thermal damage to sebaceous glands and hair, a key mechanism for their investigational acne treatment and hair removal indications.
- FDA Approves Valeant's Onexton Gel for the Treatment of Acne Vulgarishttps://practicaldermatology.com/news/fda-approves-valeants-onexton-gel-for-the-treatment-of-acne-vulgaris/2459053/The FDA approved Valeant Pharmaceuticals International, Inc.’s Onexton Gel (clindamycin phosphate and benzoyl peroxide) 1.2%/3.75% for the once-daily treatment of comedonal and inflammatory acne in patients 12 and older. "We are very pleased that the FDA has approved this new d
- Galderma Partners with AARS in Support of CDC's "Get Smart About Antibiotics Week"https://practicaldermatology.com/news/20141121-galderma_partners_with_aars_in_support_of_cdcs_get_smart_about_antibiotics_week/2459055/Galderma Laboratories, L.P. joined the American Acne and Rosacea Society (AARS) and the Centers for Disease Control and Prevention's (CDC) Get Smart About Antibiotics Week 2014 (November 17 – 23). AARS and Galderma Laboratories, the first dermatology partner to join with AARS on the initiative, are
- Gabrielle Rios, Founder of TruInject, Wins Stevie Award for Startupshttps://practicaldermatology.com/news/20141119-gabrielle_rios_founder_of_truinject_wins_stevie_award_for_startups/2459058/Gabrielle Rios, chief executive officer of TruInject Medical Corporation, received the Bronze Award at the 2014 Stevie Awards for Women in Business. The award was presented in the category of Startup of the Year. The Stevie® Awards for Women in Business honors women executives, entrepreneurs, a
- Promius Pharma Launches Promiseb Topical Cream 60 Gram Optionhttps://practicaldermatology.com/news/20141105-promius_pharma_launches_promiseb_topical_cream_60_gram_option/2459073/Promius Pharma LLC launched Promiseb Topical Cream in a new 60 gram box. This well-regarded non-steroidal cream for the treatment of seborrheic
- A Pivotal Phase III Gevokizumab Study is Initiated in Patients With Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20141104-a_pivotal_phase_3_gevokizumab_study_is_initiated_in_patients_with_pyoderma_gangrenosum/2459074/The Phase III gevokizumab study in patients with active pyoderma gangrenosum, a rare neutrophilic dermatosis of expanding necrotic skin ulcers, is open for patient enrollment. The objective of the study is to assess the efficacy and safety of gevokizumab in treating the active ulc
- SKINPACT Program Launched with New Global Awards Initiative to Support the Dermatology Communityhttps://practicaldermatology.com/news/20141010-skinpact_program_launched_with_new_global_awards_initiative_to_support_the_dermatology_community/2459088/Galderma, in partnership with the International League of Dermatological Societies, has started a search for initiatives that will fulfill an important role in strengthening the global dermatology community. Galderma launched a new global initiative un
- Researchers to Present Gigapixel Whole-Body Camera at OSA Annual Meetinghttps://practicaldermatology.com/news/20141008-researchers_to_present_gigapixel_whole-body_camera_at_osa_annual_meeting/2459091/A new “gigapixel whole-body photographic camera” may provide an option for tracking changes in potentially cancer skin lesions. Duke University researchers who developed the imaging technology will presenting it at the The Optical Society's (OSA) 98th Annual Meeting, Frontiers in Optics, Oct. 19-23
- Galderma Initiates US Study of Novel Muscle Relaxant for Aesthetic Dermatology and Cosmetic Surgeryhttps://practicaldermatology.com/news/20141006-galderma_initiates_us_study_of_novel_muscle_relaxant_for_aesthetic_dermatology_and_cosmetic_surgery/2459095/Galderma has initiated a Phase II clinical trial of a novel muscle relaxant in the US. The Phase II clinical trial is a multicenter, dose-ranging study designed to evaluate the safety and effectiveness of Galderma's internally developed liquid form of botulinum toxin for the tre
- GSK Presents Updated Results from Phase III BREAK-3 Study of Tafinlar® (dabrafenib)https://practicaldermatology.com/news/20140929-gsk_presents_updated_results_from_phase_iii_break-3_study_of_tafinlar_dabrafenib/2459102/Results from the planned analysis of the Phase III BREAK-3 study in 250 patients with BRAF V600E mutant metastatic melanoma show benefit for the use of GSK's Tafinlar (dabrafenib) over dacarbazine (DTIC). Forty-five percent of patients treated with dabrafenib only were alive at two